Literature DB >> 16778278

Tissue plasminogen activator combined with human recombinant deoxyribonuclease is effective therapy for empyema in a rabbit model.

Zhiwen Zhu1, Michael L Hawthorne, Yubiao Guo, Wonder Drake, Semra Bilaceroglu, Heather L Misra, Richard W Light.   

Abstract

OBJECTIVES: There have been no controlled studies to test the efficacy of tissue plasminogen activator (tPA) or recombinant human deoxyribonuclease (rhDNase) in the treatment of empyema. In vitro studies show that streptokinase without rhDNase does not liquefy empyemic material from rabbits. However, the combination of streptokinase and streptodornase and rhDNase have been shown to liquefy pus in vitro. The aim of this study was to determine if tPA or rhDNase, or a combination of the two, is more effective than saline solution in the treatment of empyema in rabbits.
MATERIALS AND METHODS: Empyema was induced in rabbits using 10(9) Pasteurella multicoda organisms in infusion agar injected via a surgically placed chest tube. Once empyema was verified, a blinded investigator administered one of four treatments via the chest tube: 3 mL of saline solution; 4 mg of alteplase (recombinant tPA); 1 mg of rhDNase; or 4 mg of alteplase and 1 mg of rhDNase. The rabbits received a treatment every 12 h following the initial for a total of six treatments. The animals were killed at day 10, and the degree of empyema and pleural peel was scored macroscopically on a scale of 0 to 4.
RESULTS: The combination group had a significantly lower mean empyema score (1.83 +/- 0.75) than did the saline solution group (3.86 +/- 0.38, p = 0.001), rhDNase group (3.17 +/- 0.75, p = 0.012), and alteplase group (3.71 +/- 0.49, p = 0.02) [+/- SD]. The total volume of pleural fluid was markedly higher in the alteplase and rhDNase combination group (142 +/- 79.1 mL) or the alteplase group (231 +/- 78.0 mL) compared to either the rhDNase group (0.8 +/- 1.6 mL) or the saline solution group (5.8 +/- 14.0 mL).
CONCLUSION: The combination of alteplase and rhDNase is more effective in the treatment of rabbit empyema than either agent alone. The intrapleural injection of alteplase alone or in combination with rhDNase leads to the production of large amounts of pleural fluid.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778278     DOI: 10.1378/chest.129.6.1577

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  19 in total

1.  Counterpoint: should fibrinolytics be routinely administered intrapleurally for management of a complicated parapneumonic effusion? No.

Authors:  Gene L Colice; Steven Idell
Journal:  Chest       Date:  2014-01       Impact factor: 9.410

Review 2.  Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection.

Authors:  Francesco Piccolo; Natalia Popowicz; Donny Wong; Yun Chor Gary Lee
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 3.  Intrapleural Fibrinolytic Therapy for Empyema and Pleural Loculation: Knowns and Unknowns.

Authors:  Steven Idell; Najib M Rahman
Journal:  Ann Am Thorac Soc       Date:  2018-05

4.  Effects of extracellular DNA on plasminogen activation and fibrinolysis.

Authors:  Andrey A Komissarov; Galina Florova; Steven Idell
Journal:  J Biol Chem       Date:  2011-10-05       Impact factor: 5.157

5.  Empyema thoracis.

Authors:  Ala Eldin H Ahmed; Tariq E Yacoub
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2010-06-17

6.  Intrapleural administration of DNase alone for pleural empyema.

Authors:  Vladimir Bobek; Andrzej Majewski; Katarina Kolostova; Adam Rzechonek; Robert Lischke; Jan Schutzner; Grzegorz Kacprzak
Journal:  Int J Clin Exp Med       Date:  2015-11-15

7.  Characterization of a new mouse model of empyema and the mechanisms of pleural invasion by Streptococcus pneumoniae.

Authors:  Sylwia Wilkosz; Lindsey A Edwards; Silvia Bielsa; Catherine Hyams; Abigail Taylor; Robert J O Davies; Geoffrey J Laurent; Rachel C Chambers; Jeremy S Brown; Y C Gary Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2011-09-01       Impact factor: 6.914

8.  Intrapleural therapy in management of complicated parapneumonic effusions and empyema.

Authors:  Alaeldin H Ahmed; Tariq E Yacoub
Journal:  Clin Pharmacol       Date:  2010-11-22

9.  Update on pleural diseases--2007.

Authors:  Ayman Bishay; Suhail Raoof; Adebayo Esan; Arthur Sung; Siraj Wali; Leonard Y Lee; Liziamma George; Anthony Saleh; Michael Baumann
Journal:  Ann Thorac Med       Date:  2007-07       Impact factor: 2.219

10.  The Use of Recombinant Tissue Plasminogen Activator (rTPA) in The Treatment of Fibrinous Pleuropneumonia in Horses: 25 Cases (2007-2012).

Authors:  J E Tomlinson; E Byrne; N Pusterla; K Gary Magdesian; H G Hilton; B McGorum; E Davis; A Schoster; L Arroyo; B Dunkel; H Carslake; R C Boston; A L Johnson
Journal:  J Vet Intern Med       Date:  2015-08-07       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.